Safety of mud-bath applications in moderately active rheumatoid arthritis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: To evaluate safety of mud-bath therapy in mild-moderately rheumatoid arthritis RA. Methods: We planned a randomized, double-blinded, placebo-controlled trial in patients with moderate active RA, treated with active or placebo mud applied for 15 to 20 minutes at 39 to 40°C and followed by a shower and thermal bath at 37 to 38°C for 10 to 12 minutes. The first 50 patients were evaluated for an interim analysis and considered "treated patients" without blinding breakdown. Patients were evaluated before treatment visit 1, at the end of the treatment visit 2, after four weeks visit 3, and after six months visit 4, end of the study for flare, Disease Activity Score DAS, C-reactive protein, swollen joints, Health Assessment Questionnaire, and adverse reactions. As a control group, 50 matched RA patients were enrolled at the same outpatient clinic and evaluated four weeks apart. Results: The baseline characteristics of the two groups were similar. No significant differences were noted as for disease flares. Thirty-three 66 percent treated and 12 24 percent control patients had an improvement of more than 0.6 on the DAS p

Original languageEnglish
Pages (from-to)81-87
Number of pages7
JournalJournal of Musculoskeletal Pain
Volume18
Issue number1
DOIs
Publication statusPublished - 2010

Fingerprint

Mud Therapy
Rheumatoid Arthritis
amsonic acid
Safety
Placebos
Ambulatory Care Facilities
Baths
C-Reactive Protein
Hot Temperature
Joints
Control Groups
Health
Therapeutics

Keywords

  • Flares
  • Mud-bath therapy
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

@article{ba326b9c5fe34ec0a0f53ae323ce1f4c,
title = "Safety of mud-bath applications in moderately active rheumatoid arthritis",
abstract = "Objective: To evaluate safety of mud-bath therapy in mild-moderately rheumatoid arthritis RA. Methods: We planned a randomized, double-blinded, placebo-controlled trial in patients with moderate active RA, treated with active or placebo mud applied for 15 to 20 minutes at 39 to 40°C and followed by a shower and thermal bath at 37 to 38°C for 10 to 12 minutes. The first 50 patients were evaluated for an interim analysis and considered {"}treated patients{"} without blinding breakdown. Patients were evaluated before treatment visit 1, at the end of the treatment visit 2, after four weeks visit 3, and after six months visit 4, end of the study for flare, Disease Activity Score DAS, C-reactive protein, swollen joints, Health Assessment Questionnaire, and adverse reactions. As a control group, 50 matched RA patients were enrolled at the same outpatient clinic and evaluated four weeks apart. Results: The baseline characteristics of the two groups were similar. No significant differences were noted as for disease flares. Thirty-three 66 percent treated and 12 24 percent control patients had an improvement of more than 0.6 on the DAS p",
keywords = "Flares, Mud-bath therapy, Rheumatoid arthritis",
author = "Roberto Caporali and Simona Bellometti and Silvia Rossi and Laura Bogliolo and Caterine Klersy and Carlomaurizio Montecucco",
year = "2010",
doi = "10.3109/10582450903495866",
language = "English",
volume = "18",
pages = "81--87",
journal = "Journal of Musculoskeletal Pain",
issn = "1058-2452",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Safety of mud-bath applications in moderately active rheumatoid arthritis

AU - Caporali, Roberto

AU - Bellometti, Simona

AU - Rossi, Silvia

AU - Bogliolo, Laura

AU - Klersy, Caterine

AU - Montecucco, Carlomaurizio

PY - 2010

Y1 - 2010

N2 - Objective: To evaluate safety of mud-bath therapy in mild-moderately rheumatoid arthritis RA. Methods: We planned a randomized, double-blinded, placebo-controlled trial in patients with moderate active RA, treated with active or placebo mud applied for 15 to 20 minutes at 39 to 40°C and followed by a shower and thermal bath at 37 to 38°C for 10 to 12 minutes. The first 50 patients were evaluated for an interim analysis and considered "treated patients" without blinding breakdown. Patients were evaluated before treatment visit 1, at the end of the treatment visit 2, after four weeks visit 3, and after six months visit 4, end of the study for flare, Disease Activity Score DAS, C-reactive protein, swollen joints, Health Assessment Questionnaire, and adverse reactions. As a control group, 50 matched RA patients were enrolled at the same outpatient clinic and evaluated four weeks apart. Results: The baseline characteristics of the two groups were similar. No significant differences were noted as for disease flares. Thirty-three 66 percent treated and 12 24 percent control patients had an improvement of more than 0.6 on the DAS p

AB - Objective: To evaluate safety of mud-bath therapy in mild-moderately rheumatoid arthritis RA. Methods: We planned a randomized, double-blinded, placebo-controlled trial in patients with moderate active RA, treated with active or placebo mud applied for 15 to 20 minutes at 39 to 40°C and followed by a shower and thermal bath at 37 to 38°C for 10 to 12 minutes. The first 50 patients were evaluated for an interim analysis and considered "treated patients" without blinding breakdown. Patients were evaluated before treatment visit 1, at the end of the treatment visit 2, after four weeks visit 3, and after six months visit 4, end of the study for flare, Disease Activity Score DAS, C-reactive protein, swollen joints, Health Assessment Questionnaire, and adverse reactions. As a control group, 50 matched RA patients were enrolled at the same outpatient clinic and evaluated four weeks apart. Results: The baseline characteristics of the two groups were similar. No significant differences were noted as for disease flares. Thirty-three 66 percent treated and 12 24 percent control patients had an improvement of more than 0.6 on the DAS p

KW - Flares

KW - Mud-bath therapy

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=77949372090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949372090&partnerID=8YFLogxK

U2 - 10.3109/10582450903495866

DO - 10.3109/10582450903495866

M3 - Article

AN - SCOPUS:77949372090

VL - 18

SP - 81

EP - 87

JO - Journal of Musculoskeletal Pain

JF - Journal of Musculoskeletal Pain

SN - 1058-2452

IS - 1

ER -